drugset
drugset / Trial / NCT01145768

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768 ↗

Phase 1 Completed 72 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety and tolerability of TC-5214 following oral administration of single and multiple ascending doses compared to placebo.

Timeline

Start
2010-06
Primary completion
2010-08
Completion
2010-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject dexmecamylamine Other / unclassified 4 mg Oral

Indications

No indication recorded.